平消胶囊联合卡培他滨治疗晚期乳腺癌的临床研究
|
摘要
目的探究平消胶囊联合卡培他滨片治疗晚期乳腺癌的的临床疗效。方法选取2014年12月—2017年12月在川北医学院附属医院治疗的98例晚期乳腺癌患者作为研究对象,将所有患者根据随机数字表法分为对照组和治疗组,每组各49例。对照组患者口服卡培他滨片1.25 g/m~2,2次/d,连续服用2周后停药1周;治疗组在对照组的基础上口服平消胶囊,6粒/次,3次/d。3周为1个疗程,两组患者均连续治疗2个疗程。观察两组患者的临床疗效,同时比较两组治疗前后的免疫学指标、肿瘤标志物水平、KPS评分、无进展生存期(PFS)、总体生存期(OS)。结果治疗后,对照组和治疗组患者的客观缓解率分别为22.45%、48.98%,疾病控制率分别为63.27%、85.71%,两组比较差异有统计学意义(P<0.05)。治疗后,对照组CD3~+、CD4~+、CD4~+/CD8~+水平均明显降低,治疗组CD3~+、CD4~+、CD4~+/CD8~+水平均明显升高,(P<0.05);治疗后,治疗组免疫学指标水平显著高于对照组(P<0.05)。治疗后,两组患者癌胚抗原(CEA)和血管内皮生长因子(VEGF)水平均明显降低(P<0.05);治疗后,治疗组血清肿瘤标志物水平显著低于对照组(P<0.05)。治疗后,两组患者KPS评分均显著升高(P<0.05);治疗后,治疗组KPS评分显著高于对照组(P<0.05)。治疗后,治疗组患者PFS和OS均显著高于对照组,两组比较差异具有统计学意义(P<0.05)。结论平消胶囊联合卡培他滨片治疗晚期乳腺癌具有较好的临床疗效,可以减轻化疗不良反应,提高机体免疫水平,延长患者生存期,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Pingxiao Capsules combined with Capecitabine Tablets in treatment of advanced breast cancer. Methods Patients(98 cases) with advanced breast cancer in Affiliated Hospital of North Sichuan Medical College from December 2014 to December 2017 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were po administered with Capecitabine Tablets 1.25 g/m~2, twice daily for two weeks and then stopped it for one week. Patients in the treatment group were po administered with Pingxiao Capsules on the basis of control group, 6 grains/time, three times daily. A course of treatment had three weeks, and patients in two groups were treated for two courses. After treatment, the clinical efficacy was evaluated, and the immunological indicator, serum tumor marker levels, KPS score, PFS, and OS in two groups before and after treatment were compared. Results After treatment, the objective remission rates in the control and treatment groups were 22.45% and 48.98%, respectively, and the disease control rates in the control and treatment groups were63.27% and 85.71%, respectively, and there was difference between two groups(P < 0.05). After treatment, the levels of CD3~+, CD4~+,and CD4~+/CD8~+ in the control group were significantly decreased, but the levels of CD3~+, CD4~+, and CD4~+/CD8~+ in the treatment group were significantly increased(P < 0.05). After treatment, the immunological indicator levels in the treatment group were significantly higher than those in the control group(P < 0.05). After treatment, the levels of CEA and VEGF in two groups were significantly decreased(P < 0.05). After treatment, serum tumor marker levels in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the KPS scores in two groups were significantly increased(P < 0.05). After treatment, KPS scores in the treatment group were significantly higher than those in the control group(P < 0.05). After treatment, the PFS and OS in the treatment group were significantly longer than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Pingxiao Capsules combined with Capecitabine Tablets has a good clinical effect in treatment of advanced breast cancer, can alleviate the adverse reaction of chemotherapy, improve the immune level, and prolong the survival time of patients,, which has a certain clinical application value.
Objective To investigate the clinical efficacy of Pingxiao Capsules combined with Capecitabine Tablets in treatment of advanced breast cancer. Methods Patients(98 cases) with advanced breast cancer in Affiliated Hospital of North Sichuan Medical College from December 2014 to December 2017 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were po administered with Capecitabine Tablets 1.25 g/m~2, twice daily for two weeks and then stopped it for one week. Patients in the treatment group were po administered with Pingxiao Capsules on the basis of control group, 6 grains/time, three times daily. A course of treatment had three weeks, and patients in two groups were treated for two courses. After treatment, the clinical efficacy was evaluated, and the immunological indicator, serum tumor marker levels, KPS score, PFS, and OS in two groups before and after treatment were compared. Results After treatment, the objective remission rates in the control and treatment groups were 22.45% and 48.98%, respectively, and the disease control rates in the control and treatment groups were63.27% and 85.71%, respectively, and there was difference between two groups(P < 0.05). After treatment, the levels of CD3~+, CD4~+,and CD4~+/CD8~+ in the control group were significantly decreased, but the levels of CD3~+, CD4~+, and CD4~+/CD8~+ in the treatment group were significantly increased(P < 0.05). After treatment, the immunological indicator levels in the treatment group were significantly higher than those in the control group(P < 0.05). After treatment, the levels of CEA and VEGF in two groups were significantly decreased(P < 0.05). After treatment, serum tumor marker levels in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the KPS scores in two groups were significantly increased(P < 0.05). After treatment, KPS scores in the treatment group were significantly higher than those in the control group(P < 0.05). After treatment, the PFS and OS in the treatment group were significantly longer than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Pingxiao Capsules combined with Capecitabine Tablets has a good clinical effect in treatment of advanced breast cancer, can alleviate the adverse reaction of chemotherapy, improve the immune level, and prolong the survival time of patients,, which has a certain clinical application value.
引文
[1]郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561-569.
[2]罗年安,屈亚琦,董瑞.乳腺癌的治疗进展[J].现代生物医学进展,2015,15(1):160-162.
[3]陈占红,王晓稼.晚期乳腺癌药物研究与治疗进展[J].临床药物治疗杂志,2014,12(2):1-6.
[4]Wang J,Xu B,Yuan P,et al.Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer:Phase 3 randomized trial[J].Cancer,2015,121(19):3412-3421.
[5]王金鑫,王志勇,梅其炳.平消胶囊治疗乳腺疾病的研究进展[J].世界临床药物,2016,37(2):144.
[6]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):641-703.
[7]杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[8]Friendlander A H,Ettinger R L.Karnofsky performance status scale[J].Spec Care Dentist,2010,29(4):147-148.
[9]沈敏,顾建芬,董钰英.影响乳腺癌发病的危险因素分析[J].中华全科医学,2014,12(5):782-783.
[10]Bourdeanu L,Luu T.Targeted therapies in breast cancer:implications for advanced oncology practice[J].J Adv Pract Oncol,2014,5(4):246-260.
[11]Blum J L,Dieras V,Lo Russo P M,et al.Multicenter,Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients[J].Cancer,2001,92(7):1759-1768.
[12]Morishita M,Leonard R C.Capecitabine and docetaxel combination for the treatment of breast cancer[J].Womens Health,2008,4(1):11-22.
[13]Masuda N,Lee S J,Ohtani S,et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J].NEngl J Med,2017,376(22):2147-2159.
[14]刘健,赵韬,谢佐福,等.平消胶囊抗肿瘤分子的生物学机制[J].福建医科大学学报,2006,40(4):368-372.
[15]谷泓铮,梅其炳,周斌.平消胶囊协同治疗恶性肿瘤的研究进展[J].世界临床药物,2015,36(11):789-792.
[16]梁新强,刘海洲,利基林,等.乳腺癌患者外周血T淋巴细胞和NK细胞水平分析[J].广西医学,2013,35(2):132-134.
[17]白海亚,龚晓军,刘慧民,等.CD4+/CD8+在评价局部进展期乳腺癌新辅助化疗疗效中的应用价值[J].中国优生优育,2014,20(3):129-132.
[18]王景胜,苗杰,刘正君,等.外周血T淋巴细胞亚群检测用于恶性肿瘤患者中的临床效果[J].检验医学与临床,2017,14(Z1):269-270.
[19]Grunnet M,Sorensen J B.Carcinoembryonic antigen(CEA)as tumor marker in lung cancer[J].Lung Cancer,2012,76(2):138-143.
[20]杨文蔚,王志恒,岳朝艳.乳腺癌患者血清CA153、CEA、铁蛋白和降钙素水平的变化及临床意义[J].检验医学,2017,32(4):308-310.
[21]曾强震.肿瘤标志物CA125和CEA在妇科肿瘤诊治中的临床价值分析[J].中国实用医药,2016,11(4):99-100.
[22]胡金华,张耀晴,朱斌.乳腺癌患者血清VEGF、TNF-α和IL-6的表达与预后的相关分析[J].现代肿瘤医学,2015,23(5):639-642.
[2]罗年安,屈亚琦,董瑞.乳腺癌的治疗进展[J].现代生物医学进展,2015,15(1):160-162.
[3]陈占红,王晓稼.晚期乳腺癌药物研究与治疗进展[J].临床药物治疗杂志,2014,12(2):1-6.
[4]Wang J,Xu B,Yuan P,et al.Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer:Phase 3 randomized trial[J].Cancer,2015,121(19):3412-3421.
[5]王金鑫,王志勇,梅其炳.平消胶囊治疗乳腺疾病的研究进展[J].世界临床药物,2016,37(2):144.
[6]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):641-703.
[7]杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[8]Friendlander A H,Ettinger R L.Karnofsky performance status scale[J].Spec Care Dentist,2010,29(4):147-148.
[9]沈敏,顾建芬,董钰英.影响乳腺癌发病的危险因素分析[J].中华全科医学,2014,12(5):782-783.
[10]Bourdeanu L,Luu T.Targeted therapies in breast cancer:implications for advanced oncology practice[J].J Adv Pract Oncol,2014,5(4):246-260.
[11]Blum J L,Dieras V,Lo Russo P M,et al.Multicenter,Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients[J].Cancer,2001,92(7):1759-1768.
[12]Morishita M,Leonard R C.Capecitabine and docetaxel combination for the treatment of breast cancer[J].Womens Health,2008,4(1):11-22.
[13]Masuda N,Lee S J,Ohtani S,et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J].NEngl J Med,2017,376(22):2147-2159.
[14]刘健,赵韬,谢佐福,等.平消胶囊抗肿瘤分子的生物学机制[J].福建医科大学学报,2006,40(4):368-372.
[15]谷泓铮,梅其炳,周斌.平消胶囊协同治疗恶性肿瘤的研究进展[J].世界临床药物,2015,36(11):789-792.
[16]梁新强,刘海洲,利基林,等.乳腺癌患者外周血T淋巴细胞和NK细胞水平分析[J].广西医学,2013,35(2):132-134.
[17]白海亚,龚晓军,刘慧民,等.CD4+/CD8+在评价局部进展期乳腺癌新辅助化疗疗效中的应用价值[J].中国优生优育,2014,20(3):129-132.
[18]王景胜,苗杰,刘正君,等.外周血T淋巴细胞亚群检测用于恶性肿瘤患者中的临床效果[J].检验医学与临床,2017,14(Z1):269-270.
[19]Grunnet M,Sorensen J B.Carcinoembryonic antigen(CEA)as tumor marker in lung cancer[J].Lung Cancer,2012,76(2):138-143.
[20]杨文蔚,王志恒,岳朝艳.乳腺癌患者血清CA153、CEA、铁蛋白和降钙素水平的变化及临床意义[J].检验医学,2017,32(4):308-310.
[21]曾强震.肿瘤标志物CA125和CEA在妇科肿瘤诊治中的临床价值分析[J].中国实用医药,2016,11(4):99-100.
[22]胡金华,张耀晴,朱斌.乳腺癌患者血清VEGF、TNF-α和IL-6的表达与预后的相关分析[J].现代肿瘤医学,2015,23(5):639-642.